Skip To Main Content
Sydney C.W on Muck Rack

Sydney C.W

As seen in: Frontiers, Biomed Central (BMC), TechTrends
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Sydney C.W’s profile

Articles by Sydney C.W

Association of the ratio of non-HDL-cholesterol to HDL-cholesterol with clinical and pathological characteristics in diabetic kidney disease

|
By Sydney C.W
| TechTrends
Introduction Diabetic kidney disease (DKD) is a severe complication of diabetes (DM), and dyslipidemia has a vital role in its progression. It is necessary to identify lipid-related biomarkers related to disease severity and prognosis in DKD to facilitate early risk stratification and prevent progression to advanced renal disease.
Open in Who Shared Issue with article?

Comparative performance of risk prediction models for kidney disease: an external validation using 0.5 million UK Biobank participants

|
By Chun Hin, Sydney C.W, Hin Lai Ivan
| link.springer.com
Vollset SE, Ababneh HS, Abate YH, Abbafati C, Abbasgholizadeh R, Abbasian M, et al. Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204–56. Google Scholar Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12(2):73–81.
Open in Who Shared Issue with article?

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease (pdf) | Paperity

|
By J. David, Sydney C.W, de Zeeuw, Lambers Heerspink
| paperity.org
Cardiovascular Diabetology, Sep 2023 Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association between IR and cardio-renal outcomes and the effect of the selective endothelin receptor antagonist atrasentan on IR in patients with type 2 diabetes and CKD.
Open in Who Shared Issue with article?

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease | Cardiovascular Diabetology | Full Text

|
By J. David, Sydney C.W, de Zeeuw, Lambers Heerspink
| Biomed Central (BMC)
This study is a post-hoc analysis of the RADAR and SONAR clinical trials. The study design and primary results of both trials have been published before [14, 15, 19, 20].
Open in Who Shared Issue with article?

New Insights into Fibrotic Signaling in Renal Cell Carcinoma

|
By Patrick Ming-Kuen, Sydney C.W
| Frontiers
Jiao-Yi CHEN1, Wai-Han YIU1, Patrick Ming-Kuen TANG2 and Sydney C.W. TANG1* 1Division of Nephrology, Department of Medicine, The University of Hong Kong, Hong Kong, SAR China 2Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, SAR China Provisionally accepted: The final, formatted version of the article will be published soon.
Open in Who Shared Issue with article?
Show More